Indivior Pharmaceuticals INDV
- Market cap
- $4.3B
- PE
- 10.2×
- 1y median 19.9×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.1×
- EV/EBIT
- 8.2×
- Revenue, 12 months
- $1.4B
- +16% on a year ago
- Net margin
- 32.8%
- Free cash flow yield
- 0.7%
Indivior Pharmaceuticals trades at 10.2× trailing earnings, cheaper than 98% of the last ten years. Revenue was $1.4B over the last twelve months, up 16% on a year earlier with a 33% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $284M | $299M | $307M | $299M | $266M−6% | $302M+1% | $314M+2% | $358M+20% | $317M+19% | $343M+14% | $356M+13% | |
| Cost of revenue | $38M | $79M | $66M | $48M | $44M+16% | $52M−34% | $83M+26% | $67M+40% | $40M−9% | $50M−4% | $51M−39% |
| Gross profit | $246M | $220M | $241M | $250M | $221M−10% | $250M+14% | $230M−5% | $292M+17% | $277M+25% | $294M+18% | $305M+33% |
| R&D | $28M | $26M | $22M | $31M | $22M−21% | $21M−19% | $33M+50% | $21M−32% | $16M−27% | $12M−43% | $5M−85% |
| SG&A | $143M | $152M | $142M | $175M | $133M−7% | $158M+4% | $154M+9% | $189M+8% | $124M−7% | $122M−23% | $119M−23% |
| $75M | −$118M | $35M | $46M | $66M−12% | $72M | $43M+23% | $81M+76% | $137M+108% | $160M+122% | $180M+319% | |
| Interest expense | $9M | $9M | $11M | $13M | $12M+33% | $15M+67% | $12M+9% | $6M−54% | $7M−42% | $2M−87% | $2M−83% |
| Pre-tax income | $73M | −$121M | $30M | $38M | $59M−19% | $62M | $37M+23% | $81M+113% | $115M+95% | $160M+158% | $182M+392% |
| $11M | −$23M | $8M | $17M | $11M+0% | $44M | −$5M | −$21M | $26M+136% | $38M−14% | $45M | |
| Net income | $61M | −$97M | $22M | $21M | $47M−23% | $18M | $42M+91% | $102M+386% | $89M+89% | $122M+578% | $137M+226% |
| $0.45 | −$0.72 | $0.16 | $0.17 | $0.38−16% | $0.14 | $0.33+106% | $0.78+359% | $0.69+82% | $0.98+600% | $1.12+239% | |
| 137M | 135M | 133M | 127M | 125M−9% | 126M−7% | 129M−3% | 131M+3% | 129M+3% | 124M−2% | 122M−5% |
EPS, diluted: Q4 FY24 and Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Indivior Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| INDVIndivior Pharmaceuticals | $4.3B | 10.2× | 19.9× | 3.1× | +16% | 32.8% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 117× | 8.5× | +76% | 6.1% | |
| LQDALiquidia | $3.7B | 30.1× | 49.4× | 8.3× | n/m | 30.7% | |
| OGNOrganon | $3.6B | 18.2× | 6.0× | 0.6× | −3% | 3.5% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.7× | 37.6× | 21.1× | +55% | 67.9% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.7× | 51.4× | 2.1× | +9% | 5.0% | |
| NRIXNurix Therapeutics | $2.8B | 11.1× | 11.0× | 4.0× | n/m | 42.0% | |
| KNSAKiniksa Pharmaceuticals International | $7.1B | 93.6× | 87.6× | 8.4× | +59% | 9.6% | |
| ALKSAlkermes plc. | $7.5B | 118× | 16.0× | 4.5× | +11% | 4.0% | |
| PBHPrestige Consumer Healthcare | $2.4B | 13.9× | 15.3× | 2.1× | −1% | 15.6% | |
| HRMYHarmony Biosciences | $2.2B | 12.3× | 13.8× | 2.3× | +24% | 18.9% | |
| Peer median | $3.8B | 31.4× | 26.8× | 4.3× | +18% | 12.6% |
More on Indivior Pharmaceuticals
Each number over time
Where it ranks
- #4of 135Healthcare stocks with the fastest earnings growth
- #1of 24Large drugmakers with the fastest earnings growth
- #10of 170Healthcare stocks with the lowest PE ratio
- #6of 41Large drugmakers with the lowest PE ratio
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .